AlphaGrep UK’s Nurix Therapeutics NRIX Stock Holding History

AlphaGrep UK’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19,096	Closed	-$296K	–	886
2026 Q1	$296K	Buy	+19,096	New	+$317K	0.09%	517

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

AlphaGrep UK's NRIX Position: Q2 2026 in Review

AlphaGrep UK sold out of Nurix Therapeutics (NRIX) in Q2 2026, closing a stake of 19,096 shares — an estimated $296K sold.

AlphaGrep UK first reported a position in NRIX in Q1 2026 and held it in 1 quarter. The position peaked at $296K in Q1 2026. 194 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

AlphaGrep UK reported no remaining Nurix Therapeutics position as of Q2 2026 after selling out during the quarter.
AlphaGrep UK sold 19,096 Nurix Therapeutics shares in Q2 2026, an estimated $296K.
AlphaGrep UK first reported a position in Nurix Therapeutics in Q1 2026 and held it in 1 quarter.
AlphaGrep UK's Nurix Therapeutics position peaked at $296K in Q1 2026.
194 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on AlphaGrep UK's 13F filing for Q2 2026, filed 14 Aug 2026.